This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Prajmaline
- DrugBank Accession Number
- DB13555
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Prajmaline (DB13555)
- Weight
- Average: 369.528
Monoisotopic: 369.253654731 - Chemical Formula
- C23H33N2O2
- Synonyms
- Prajmalium
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Acebutolol may increase the arrhythmogenic activities of Prajmaline. Acetyldigitoxin Acetyldigitoxin may increase the arrhythmogenic activities of Prajmaline. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Prajmaline. Adenosine Adenosine may increase the arrhythmogenic activities of Prajmaline. Ajmaline Ajmaline may increase the arrhythmogenic activities of Prajmaline. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Prajmaline. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Prajmaline. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Prajmaline. Amifampridine The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Amifampridine. Amiodarone Amiodarone may increase the QTc-prolonging activities of Prajmaline. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- C01BA08 — Prajmaline
- Drug Categories
- Alkaloids
- Antiarrhythmic agents
- Antiarrhythmics, Class I
- Antiarrhythmics, Class Ia
- Antiarrhythmics, Class Ic
- Cardiac Therapy
- Cardiovascular Agents
- Heterocyclic Compounds, Fused-Ring
- Indole Alkaloids
- Indoles
- Indolizidines
- Indolizines
- Potential QTc-Prolonging Agents
- QTc Prolonging Agents
- Secologanin Tryptamine Alkaloids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as ajmaline-sarpagine alkaloids. These are organic compounds containing either of the ajmalan, sarpagan skeleton, or derivative thereof. The Sarpagine (Akuammidine) group, based on the sarpagan nucleus, arises from bond formation between C-16 and C-5 of the corynantheine precursor. Ajmaline alkaloids are based on a 17,19-secoyohimban skeleton (oxayohimban) which is invariably present as an ether.
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Ajmaline-sarpagine alkaloids
- Sub Class
- Not Available
- Direct Parent
- Ajmaline-sarpagine alkaloids
- Alternative Parents
- Beta carbolines / Quinolizidines / Quinuclidines / Dialkylarylamines / Aralkylamines / Azepanes / Benzenoids / Piperidines / Tetraalkylammonium salts / Hemiaminals show 7 more
- Substituents
- Alcohol / Alkanolamine / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azepane / Benzenoid / Beta-carboline / Cyclic alcohol show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 75934UD4GJ
- CAS number
- 35080-11-6
- InChI Key
- UAUHEPXILIZYCU-ALHOSYKFSA-N
- InChI
- InChI=1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1
- IUPAC Name
- (1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-14,18-dihydroxy-8-methyl-15-propyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2(7),3,5-trien-15-ium
- SMILES
- CCC[N@@+]12[C@H]3C[C@]45[C@H](O)[C@H]3[C@@H](C[C@H]1[C@@H]4N(C)C1=C5C=CC=C1)[C@H](CC)[C@H]2O
References
- General References
- Not Available
- External Links
- ChemSpider
- 34986954
- 8622
- ChEBI
- 135560
- ZINC
- ZINC000252462538
- Wikipedia
- Prajmaline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0299 mg/mL ALOGPS logP 2.24 ALOGPS logP -1.4 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 12.01 Chemaxon pKa (Strongest Basic) -0.54 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 43.7 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 117.75 m3·mol-1 Chemaxon Polarizability 42.74 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at June 23, 2017 20:44 / Updated at June 12, 2020 16:53